4 quarters tracked · Beat rate 50% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $-1.69 | $-1.67 | +0.9% | Beat |
| Q4 2025 | 2025-12-31 | $-1.49 | $-1.50 | -1.0% | Miss |
| Q3 2025 | 2025-09-30 | $-1.61 | $-2.55 | -58.2% | Miss |
| Q2 2025 | 2025-06-30 | $-1.41 | $-1.12 | +20.3% | Beat |
Earnings Beat Rate
Cytokinetics has beaten analyst EPS estimates in 2 of 4 tracked quarters (50% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →